Patient age as a predictive factor in biochemical recurrence following brachytherapy: Oncological outcomes at a single center

Iinuma, 2020, Assessment of Long-term Changes in Lower Urinary Tract Symptoms in Patients With Prostate Cancer Who Underwent Low-dose-rate Prostate Brachytherapy, Urology, 142, 213, 10.1016/j.urology.2020.04.106 Mottet, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 79, 243, 10.1016/j.eururo.2020.09.042 Stone, 2022, Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy, Brachytherapy, 10.1016/j.brachy.2022.01.001 Lester-Coll, 2013, Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis, Cancer, 119, 1808, 10.1002/cncr.27980 Roach, 2006, Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int J Radiat Oncol Biol Phys, 65, 965, 10.1016/j.ijrobp.2006.04.029 Zimmermann, 2018, Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease, J Contemp Brachytherapy, 10, 297, 10.5114/jcb.2018.77949 Zelefsky, 2012, Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience, Brachytherapy, 11, 245, 10.1016/j.brachy.2011.08.003 Forsythe, 2012, Predictors of metastatic disease after prostate brachytherapy, Int J Radiat Oncol Biol Phys, 83, 645, 10.1016/j.ijrobp.2011.07.033 Taira, 2012, Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer, Int J Radiat Oncol Biol Phys, 82, e225, 10.1016/j.ijrobp.2011.04.046 Meynard, 2019, Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers, Radiat Oncol, 15, 1, 10.1186/s13014-019-1449-z Reis, 2014, PSA-nadir at 1 year as a sound contemporary prognostic factor for low-dose-rate iodine-125 seeds brachytherapy, World J Urol, 32, 753, 10.1007/s00345-013-1148-6 Stone, 2009, Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy, Int J Radiat Oncol Biol Phys, 73, 341, 10.1016/j.ijrobp.2008.04.038 Burri, 2010, Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer, Int J Radiat Oncol Biol Phys, 77, 1315, 10.1016/j.ijrobp.2009.06.052 Buyyounouski, 2017, Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, 67, 245, 10.3322/caac.21391 Taniguchi, 2020, Predictive factors of rectal hemorrhage in patients with localized prostate cancer who underwent low-dose-rate brachytherapy, Int J Clin Oncol, 25, 1711, 10.1007/s10147-020-01713-x Stone, 2012, Factors influencing urinary symptoms 10 years after permanent prostate seed implantation, J Urol, 187, 117 Ohashi, 2007, Comparison of intraoperative ultrasound with postimplant computed tomography--dosimetric values at Day 1 and Day 30 after prostate brachytherapy, Brachytherapy, 6, 246, 10.1016/j.brachy.2007.08.006 Tanaka, 2007, Effect of edema on postimplant dosimetry in prostate brachytherapy using CT/MRI fusion, Int J Radiat Oncol Biol Phys, 69, 614, 10.1016/j.ijrobp.2007.05.082 Perkins, 2006, The inconsistency of ‘optimal’ cutpoints obtained using two criteria based on the receiver operating characteristics curve, Am J Epidemiol, 163, 670, 10.1093/aje/kwj063 Ito, 2018, Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival, Int J Clin Oncol, 23, 1148, 10.1007/s10147-018-1309-0 Brenner, 2000, Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery, Cancer, 88, 398, 10.1002/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO;2-V Moon, 2006, Cancer incidence after localized therapy for prostate cancer, Cancer, 107, 991, 10.1002/cncr.22083 Kim, 2009, Tumor self-seeding by circulating cancer cells, Cell, 139, 1315, 10.1016/j.cell.2009.11.025 Kaplan, 2005, VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche, Nature, 438, 820, 10.1038/nature04186 McAllister, 2008, Systemic endocrine instigation of indolent tumor growth requires osteopontin, Cell, 133, 994, 10.1016/j.cell.2008.04.045 Abdel-Wahab, 2008, Second primary cancer after radiotherapy for prostate cancer - a SEER analysis of brachytherapy versus external beam radiotherapy, Int J Radiat Oncol Biol Phys, 72, 58, 10.1016/j.ijrobp.2007.12.043 Sanguedolce, 2021, Radiation-induced haemorrhagic cystitis after prostate cancer radiotherapy: factors associated to hospitalization and treatment strategies, Prostate Int, 9, 48, 10.1016/j.prnil.2020.07.006 Shapiro, 2009, Long-term outcomes in younger men following permanent prostate brachytherapy, J Urol, 181, 1665 Litwin, 2007, Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer, Cancer, 109, 2239, 10.1002/cncr.22676 Sanda, 2008, Quality of life and satisfaction with outcome among prostate-cancer survivors, N Eng J Med, 358, 1250, 10.1056/NEJMoa074311